Search results
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World...
FOX 5 San Diego· 10 hours agoDALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today ...
Experimental gene therapy restores some vision in patients with inherited blindness
CNN via Yahoo News· 1 day agoFor her entire life, college student Olivia Cook had only a small degree of central vision. It was...
Ocugen stock is a good speculative buy but there’s 1 key risk
Invezz· 7 hours agoOcugen (NASDAQ: OCGN) stock price has launched higher since last year, helped by the rising hopes...
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial...
Benzinga· 6 days agoATSN-201 utilizes AAV.SPR, the company's novel spreading capsid, to achieve therapeutic levels of gene expression in photoreceptors of the central retina while avoiding the ...
CRIPSR gene editing leads to improvements in vision for people with inherited blindness, clinical...
Medical Xpress· 1 day ago"This research demonstrates that CRISPR gene therapy for inherited vision loss is worth continued...
China's 'lobster eye' Einstein telescope releases 1st batch of trippy space images
Live Science via Yahoo News· 4 days agoOne the right is a diagram of the size of these square pores. (Image credit: ESA/J. ...purpose. The...
A Revolution In Gene Therapy Is Unfolding, Bringing Hope for Vision Loss
Newswise· 5 days agoTwo treatments for retinal diseases, invented by Neena Haider, PhD, that currently are in clinical trials run by Ocugen, represent a conceptually broad, new approach that ...
Operational Implications of the New Bulk Sensitive Data Executive Order | JD Supra
JD Supra· 14 hours agoThe United States Department of Justice (DOJ) concurrently published an Advanced Notice of Proposed Rulemaking (the “ANPRM”) to commence the process of establishing regulations that will effectuate ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 10 hours agoGenerated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® (pegcetacoplan injection) $25.6 million for EMPAVELI® (pegcetacoplan) Anticipates CHMP opinion for pegcetacoplan in GA
The Apple Studio Display has returned to its lowest ever price on Amazon
Neowin· 5 days agoThe Apple Studio Display is back down to its all-time low price of $1,299.97. It was there a few months ago, but Apple returned it to its old price, which was hundreds of dollars more.